AbbVie executives conducted stock transactions in mid-November
AbbVie Inc. executives Jeffrey R. Stewart and Azita Saleki-Gerhardt conducted a series of company stock transactions between November 9 and November 16, 2026. The executives exercised stock options and filed notices of proposed sales as part of managing their personal equity holdings.
Key points
- Jeffrey R. Stewart, executive vice president and chief commercial officer, exercised options to acquire 40,619 shares on November 9, 2026.
- Aside from option transactions, Jeffrey R. Stewart gifted 3,450 company shares on November 12, 2026.
- External observers may view insider stock sales, even those linked to option exercises, as a signal of reduced confidence in the company’s value.
Executive stock transactions
Jeffrey R. Stewart, executive vice president and chief commercial officer, exercised options to acquire 40,619 shares on November 9, 2026. He sold the same number of shares on the open market that day. Following these transactions, he holds 83,171 AbbVie shares.
On November 16, 2026, Azita Saleki-Gerhardt filed a notice of a proposed sale for 13,481 shares acquired through option exercises. It is important to note that such a notice does not mean the sale has already occurred.
Proposed sales (Form 144), by insider
Other ownership changes
Aside from option transactions, Jeffrey R. Stewart gifted 3,450 company shares on November 12, 2026. His AbbVie stake decreased to 79,721 shares after this transaction.
Risks for shareholders
External observers may view insider stock sales, even those linked to option exercises, as a signal of reduced confidence in the company’s value. Executive trades are personal financial decisions and do not indicate changes to AbbVie’s outlook or financial policy.
What to watch
Shareholders should monitor future insider transaction reports in the SEC EDGAR database. These filings will indicate whether executives continue to divest shares or if they initiate new transactions to maintain holdings.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow AbbVie
A notification in your browser or on your phone when we publish about AbbVie. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
